| Compound |
Company |
Primary Therapeutical Area / Indication |
Drug development |
|
| HMD-301 (HBP) |
|
Bacterial and Fungal Diseases / Sepsis |
Phase II
|
 |
|
|
| BKG HU3-28 |
BKG Pharma
|
Bacterial and Fungal Diseases |
Pre-clinical
|
 |
|
|
| BKG HUR10-7 |
BKG Pharma
|
Bacterial and Fungal Diseases |
Pre-clinical
|
 |
|
|
| BKG Q04HU |
BKG Pharma
|
Bacterial and Fungal Diseases |
Pre-clinical
|
 |
|
|
| BKG S21HU |
BKG Pharma
|
Bacterial and Fungal Diseases |
Pre-clinical
|
 |
|
|
| EV-035 |
Evolva A/S
|
Bacterial and Fungal Diseases / Bacterial Infections |
Pre-clinical
|
 |
|
|
| MVA-BN Anthrax |
|
Bacterial and Fungal Diseases / Anthrax |
Pre-clinical
|
 |
|
|
| NZ17000 |
|
Bacterial and Fungal Diseases / Escherichia coli Infections |
Pre-clinical
|
 |
|
|
| NZ2114/SAR215500 |
|
Bacterial and Fungal Diseases / Staphylococcal Infections |
Pre-clinical
|
 |
|
|
| Sym006 |
|
Bacterial and Fungal Diseases / Pseudomonas Infections |
Pre-clinical
|
 |
|
|
| TM-120 |
|
Bacterial and Fungal Diseases / Sepsis |
Pre-clinical
|
 |
|
|